**Index 1:**

**Search Strategy: Done on June, 2023**

|  |  |  |
| --- | --- | --- |
| Set | **PubMed** | Results |
| #1 | "Heart Neoplasms"[Mesh] | 17,268 |
| #2 | "Fetus"[Mesh] | 164,046 |
| #3 | #1 AND #2 | **70** |
| Set | **Scopus** | Results |
| #1 | TITLE-ABS-KEY (fetal OR fetus OR prenatal OR perinatal OR antenatal) | 827,297 |
| #2 | TITLE-ABS-KEY ("cardiac tumor" OR "heart tumor" OR “heart rhabdomyoma” OR “cardiac rhabdomyoma” OR "cardiac neoplasm" OR "heart neoplasm" OR "cardiac mass" OR "heart mass") | 21,312 |
| #3 | TITLE-ABS-KEY (therap\* OR treatment OR sirolimus OR everolimus OR "mTOR inhibitor" OR intervetion$ OR management) | 20,715,037 |
| #4 | TITLE-ABS-KEY (“fetal bovine serum”) | 14,527 |
| #5 | #1 AND #2 AND #3 AND NOT #4 | **304** |
| Set | **Web of Science** | Results |
| #1 | TS=(fetal OR fetus OR prenatal OR perinatal OR antenatal)  | 476,815 |
| #2 | TS=("cardiac tumor" OR "heart tumor" OR rhabdomyoma OR "cardiac neoplasm" OR "heart neoplasm" OR "cardiac mass" OR "heart mass") | 4,332 |
| #3 | TS=(therap\* OR treatment OR sirolimus OR everolimus OR "mTOR inhibitor" OR drug OR intervetion$ OR management) | 10,010,109 |
| #4 | #1 AND #2 AND #3 | **149** |

**Index 2:**

**Risk of bias assessment for the included studies using Joanna Briggs Institute critical appraisal tool for case reports and case series**

**Case reports**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Year of publication** | **Were patient’s demographic characteristics clearlydescribed?** | **Was the patient’s history clearly described and presentedas a timeline?** | **Was the current clinical condition of the patient onpresentation clearly described?** | **Were diagnostic tests or assessment methods and theresults clearly described?** | **Was the intervention(s) or treatment procedure(s) clearlydescribed?** | **Was the post-intervention clinical condition clearlydescribed?** | **Were adverse events (harms) or unanticipated eventsidentified and described?** | **Does the case report provide takeaway lessons?** | **Overall** |
| Lacey | 2007 | Yes | Yes | No | Yes | Not applicable | Yes | Not applicable | Yes | 5 |
| Takeuchi | 2006 | Yes | Yes | Yes | Yes | Not applicable | Not applicable | Not applicable | Not clear | 4 |
| Hoadley | 1986 | Yes | Not clear | Yes | Yes | Yes | Yes | No | Yes | 6 |
| Birnbaum | 1985 | No | No | Not clear | Yes | Not applicable | Yes | Not clear | Yes | 3 |
| PLUYM | 2020 | No | Not clear | Yes | Yes | Yes | Yes | Yes | Yes | 6 |
| Amelia | 2013 | Yes | Not clear | No | Yes | Not applicable | Yes | Not applicable | Yes | 4 |
| Devore | 1981 | No | No | Yes | Yes | Yes | Not applicable | Not applicable | Yes | 4 |
| Dagge | 2021 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 7 |
| Vincenzo D' Addario | 2001 | No | No | Yes | Yes | No | Yes | Not clear | Yes | 4 |
| Atalay | 2010 | No | No | Yes | Yes | Not applicable | Yes | Not clear | Yes | 4 |
| Phillip | 2021 | Yes | Yes | Yes | Yes | Not applicable | Not applicable | Not applicable | Not applicable | 4 |
| Sarff | 2019 | No | No | Yes | Yes | Not applicable | Yes | Not applicable | Yes | 4 |
| Gazit | 2007 | No | No | Yes | Yes | Not applicable | Yes | Not applicable | Yes | 4 |
| King | 2005 | No | Yes | Yes | Yes | Not applicable | Yes | Not applicable | Yes | 5 |
| Eirich | 2002 | Yes | Yes | Yes | Yes | Not applicable | Yes | Not applicable | Not clear | 5 |
| Bonnamy | 2001 | Yes | Yes | Yes | Yes | Not applicable | Yes | Not applicable | Not clear | 5 |
| Habanova | 2021 | No | No | Yes | Yes | Not applicable | Yes | Not applicable | Yes | 4 |
| Daniel Ebrahimi-Fakhari | 2021 | No | No | Yes | Yes | Not applicable | Yes | Not applicable | Yes | 4 |
| Patel | 2018 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | 6 |
| Lefizelier | 2021 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Deeg | 1989 | Not clear | No | Yes | Yes | Yes | Yes | Not clear | Not clear | 6 |
| Gresser | 1987 | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | 7 |
| Schaffer | 1986 | No | No | Yes | Yes | Yes | No | Not clear | Not clear | 5 |
| Boxer | 1986 | Not clear | No | Yes | Yes | Yes | No | Yes | Yes | 6 |
| Lollo | 1984 | Yes | Yes | Yes | Yes | Not applicable | Not clear | Not applicable | Not applicable | 4 |
| Marceau | 2019 | No | No | Yes | Yes | Yes | Yes | Not applicable | Not clear | 6 |
| Barnes | 2018 | No | No | Yes | Yes | Not applicable | Yes | Not applicable | Yes | 5 |
| Mendes | 2017 | No | No | Yes | Yes | Yes | Yes | Not applicable | Not clear | 6 |
| Ekmekci | 2018 | Not clear | No | Yes | Yes | Yes | Not clear | No | Yes | 4 |
| Park | 2019 | Yes | Yes | Yes | Yes | Yes | Yes | Not applicable | Not applicable | 6 |
| Shivananjaiah | 2015 | No | No | Yes | Yes | Not clear | Yes | Not clear | Yes | 4 |
| MLczoch | 2015 | No | Yes | Yes | Yes | No | Yes | Not clear | Not clear | 4 |
| Mir | 2014 | No | Yes | Yes | Yes | Not clear | Yes | Yes | Not clear | 5 |
| Rhodes | 2014 | No | No | Yes | Yes | Yes | Yes | Yes | Not clear | 5 |
| Marshall | 2014 | Yes | No | Yes | Yes | Not clear | Yes | Not applicable | Not applicable | 4 |

**Case series**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Year of publication** | **Were there clear criteria for inclusion in the caseseries?** | **Was the condition measured in a standard, reliableway for all participants included in the case series?** | **Were valid methods used for identification of thecondition for all participants included in the caseseries?** | **Did the case series have consecutive inclusion ofparticipants?** | **Did the case series have complete inclusion ofparticipants?** | **Was there clear reporting of the demographics ofthe participants in the study?** | **Was there clear reporting of clinical information ofthe participants?** | **Were the outcomes or follow up results of casesclearly reported?** | **Was there clear reporting of the presentingsite(s)/clinic(s) demographic information?** | **Was statistical analysis appropriate?** | **Overall** |
| Chao | 2007 | Yes | Yes | Yes | Yes | Yes | No | Not clear | Yes | Not clear | Yes | 7 |
| Behram | 2020 | Yes | Yes | Yes | Yes | No | Not clear | Yes | Yes | Not clear | Yes | 7 |
| Holley | 1995 | Yes | Yes | Yes | Yes | Yes | No | No | Yes | Not clear | Yes | 7 |
| Mariscal |  | Yes | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | 7 |
| Fesslova | 2004 | Yes | Yes | Yes | Yes | Yes | Not clear | No | Yes | Not clear | Yes | 7 |
| Bejiqi | 2017 | Yes | Yes | Yes | Yes | Yes | No | No | Yes | Not clear | Yes | 7 |
| Okmen | 2020 | Yes | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | 7 |
| Wallace | 1989 | Not clear | Yes | Yes | Yes | Not clear | No | Not clear | Yes | No | No | 7 |
| Wacker gussman | 2014 | Yes | Yes | Yes | Yes | Not clear | No | Yes | Yes | No | Yes | 7 |
| Pucci | 2013 | Yes | Yes | Yes | Yes | Yes | Not clear | No | Yes | Not clear | Yes | 7 |
| Lopez | 2011 | Yes | Yes | Yes | Yes | Yes | Not clear | No | Yes | Not clear | Yes | 7 |